Description

Mounjaro KwikPen 5mg Injection

MOUNJARO 5mg contains tirzepatide, a dual GIP and GLP-1 receptor agonist, administered as an easy-to-use, subcutaneous (under-the-skin) injection in the abdomen, thigh, or upper arm. Its advanced formula is FDA-approved and backed by clinical studies, delivering significant improvements in blood sugar control and promoting sustainable weight management for adults struggling with type 2 diabetes.​

Uses

• Controls blood sugar in adults diagnosed with type 2 diabetes, particularly for those who haven’t reached targets with oral medicines or lifestyle changes alone.​

• Supports weight loss in overweight or obese patients by reducing appetite and slowing digestion.​

• Can be prescribed in combination with other diabetes medicines including metformin, sulphonylureas, or basal insulin if required.​

Precautions

• Not for patients with type 1 diabetes or a history of pancreatitis.​

• May increase risk of thyroid C-cell tumors (shown in animals); consult your physician before starting if you have a history of thyroid issues.​

• Use caution in people with diabetic retinopathy, kidney problems, or a history of pancreatitis.

• Rotate injection sites to prevent skin irritation or lumps, and inspect the solution for clarity before use.​

• Common side effects: nausea, vomiting, diarrhea, abdominal pain, constipation. Rare but serious effects: pancreatitis, gallbladder problems, acute kidney injury, increased heart rate.​

• Always follow your healthcare provider’s guidance on dosage and administration, and monitor blood sugar regularly to avoid hypoglycemia.​

FAQs

Q: When and how is MOUNJARO injected?
A: Once a week, same day each week, anytime, at the abdomen, thigh, or upper arm. Rotate sites for each injection.​

Q: Can I use MOUNJARO with other diabetes medications?
A: Yes, it may be used with metformin, sulphonylureas, SGLT2 inhibitors, or basal insulin if prescribed by your doctor.​

Q: What if I miss a dose?
A: Take your next dose as soon as possible within 4 days; otherwise, skip the dose and maintain your regular schedule. Never take two doses at once.​

Q: Can it be used for weight loss alone?
A: Approved for obesity management in several countries; consult your doctor to see if it’s suitable for you.​

Q: Are there serious side effects?
A: Risk of thyroid tumors, pancreatitis, and acute kidney injury exist. Report persistent nausea, abdominal pain, yellow skin, or vision changes.​

Interesting to Know

• MOUNJARO is the first dual GIP/GLP-1 agonist available, offering unique benefits over older diabetes injectables.​

• Results from the SURPASS-5 trial showed an average HbA1c reduction of over 2% and weight loss of 5–10 kg at standard doses, making it a leading choice for diabetes and weight management.​

• Safe for most adults but should always be prescribed and monitored by a qualified healthcare professional.​